Switch theme
Sign up to access all valuation multiples
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
1993
1.5K+
LTM Revenue $1.4B
LTM EBITDA -$53.9M
$738M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DocMorris has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of -$53.9M.
In the most recent fiscal year, DocMorris achieved revenue of $1.3B and an EBITDA of -$47.4M.
DocMorris expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DocMorris valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $306M | XXX | $273M | XXX | XXX | XXX |
| Gross Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA | -$53.9M | XXX | -$47.4M | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | -4% | XXX | XXX | XXX |
| EBIT | -$112M | XXX | -$131M | XXX | XXX | XXX |
| EBIT Margin | -8% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$124M | XXX | -$122M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $240M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, DocMorris's stock price is CHF 8 (or $10).
DocMorris has current market cap of CHF 370M (or $465M), and EV of CHF 586M (or $738M).
See DocMorris trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $738M | $465M | XXX | XXX | XXX | XXX | $-3.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, DocMorris has market cap of $465M and EV of $738M.
DocMorris's trades at 0.6x EV/Revenue multiple, and -15.6x EV/EBITDA.
Equity research analysts estimate DocMorris's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DocMorris has a P/E ratio of -3.8x.
See valuation multiples for DocMorris and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $465M | XXX | $465M | XXX | XXX | XXX |
| EV (current) | $738M | XXX | $738M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | -13.7x | XXX | -15.6x | XXX | XXX | XXX |
| EV/EBIT | -6.6x | XXX | -5.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.8x | XXX | -3.8x | XXX | XXX | XXX |
| EV/FCF | -9.8x | XXX | -10.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDocMorris's last 12 month revenue growth is 18%
DocMorris's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.3M for the same period.
DocMorris's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DocMorris's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DocMorris and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | -40% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 12% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DocMorris acquired XXX companies to date.
Last acquisition by DocMorris was XXXXXXXX, XXXXX XXXXX XXXXXX . DocMorris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DocMorris founded? | DocMorris was founded in 1993. |
| Where is DocMorris headquartered? | DocMorris is headquartered in Switzerland. |
| How many employees does DocMorris have? | As of today, DocMorris has 1.5K+ employees. |
| Is DocMorris publicy listed? | Yes, DocMorris is a public company listed on SWX. |
| What is the stock symbol of DocMorris? | DocMorris trades under DOCM ticker. |
| When did DocMorris go public? | DocMorris went public in 2017. |
| Who are competitors of DocMorris? | Similar companies to DocMorris include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of DocMorris? | DocMorris's current market cap is $465M |
| What is the current revenue of DocMorris? | DocMorris's last 12 months revenue is $1.4B. |
| What is the current revenue growth of DocMorris? | DocMorris revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of DocMorris? | Current revenue multiple of DocMorris is 0.5x. |
| Is DocMorris profitable? | Yes, DocMorris is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DocMorris? | DocMorris's last 12 months EBITDA is -$53.9M. |
| What is DocMorris's EBITDA margin? | DocMorris's last 12 months EBITDA margin is -4%. |
| What is the current EV/EBITDA multiple of DocMorris? | Current EBITDA multiple of DocMorris is -13.7x. |
| What is the current FCF of DocMorris? | DocMorris's last 12 months FCF is -$75.1M. |
| What is DocMorris's FCF margin? | DocMorris's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of DocMorris? | Current FCF multiple of DocMorris is -9.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
